Conray 30

NDA 16983, held by Liebel-Flarsheim. Iothalamate Meglumine.

As of Nov 13, 2026, NDA 16983 (Conray 30), held by Liebel-Flarsheim, was first approved by FDA on Aug 6, 1971, with 28 approved supplements and 0 published complete response letters.

First approved: Aug 6, 1971
Review: Standard
Supplements approved: 28
Complete response letters: 0

Approvals and New Uses

The original application and every efficacy supplement, newest first; all 29 submissions below

Date	Submission	Status	Documents
Sep 9, 1985	Supplement 20Efficacy (new indication or use)	Approved	None posted
Jun 20, 1977	Supplement 9Efficacy (new indication or use)	Approved	None posted
Aug 6, 1971	Original applicationNew formulation or manufacturer · Standard review	Approved	None posted

Products

1 strengths and forms

Product	Active ingredient	Marketing
Conray 3030% · injectable;injection	Iothalamate Meglumine	DiscontinuedReference drug

All 29 submissions, including labeling and manufacturing supplements

Date	Submission	Status	Documents
Apr 5, 2017	Supplement 37Labeling · Standard review	Approved	Letter Label
Jul 6, 2015	Supplement 35Labeling	Approved	Letter Label
Dec 19, 2013	Supplement 32Manufacturing · Standard review	Approved	None posted
May 10, 2013	Supplement 30Manufacturing · Standard review	Approved	None posted
Oct 27, 1999	Supplement 29Manufacturing · Standard review	Approved	None posted
Jan 13, 1995	Supplement 28Labeling · Standard review	Approved	None posted
Dec 4, 1992	Supplement 26Manufacturing · Standard review	Approved	None posted
Aug 28, 1992	Supplement 27Manufacturing · Standard review	Approved	None posted
Mar 30, 1990	Supplement 25Manufacturing · Standard review	Approved	None posted
Dec 1, 1989	Supplement 23Manufacturing · Standard review	Approved	None posted
Oct 10, 1989	Supplement 22Manufacturing · Standard review	Approved	None posted
Jun 28, 1989	Supplement 18Manufacturing · Standard review	Approved	None posted
Jun 12, 1989	Supplement 24Labeling	Approved	None posted
Sep 9, 1985	Supplement 20Efficacy (new indication or use)	Approved	None posted
Apr 8, 1985	Supplement 21Manufacturing · Standard review	Approved	None posted
Dec 4, 1984	Supplement 17Manufacturing · Standard review	Approved	None posted
Nov 7, 1984	Supplement 19Labeling	Approved	None posted
Jun 25, 1984	Supplement 16Manufacturing · Standard review	Approved	None posted
Aug 16, 1982	Supplement 15Labeling	Approved	None posted
Aug 16, 1982	Supplement 13Labeling	Approved	None posted
Aug 24, 1981	Supplement 14Manufacturing · Standard review	Approved	None posted
Jun 20, 1977	Supplement 9Efficacy (new indication or use)	Approved	None posted
Sep 8, 1976	Supplement 11Manufacturing · Standard review	Approved	None posted
May 5, 1976	Supplement 10Labeling	Approved	None posted
May 5, 1976	Supplement 8Manufacturing · Standard review	Approved	None posted
Jan 23, 1976	Supplement 7Manufacturing · Standard review	Approved	None posted
Jan 23, 1976	Supplement 6Manufacturing · Standard review	Approved	None posted
Jul 30, 1975	Supplement 5Manufacturing · Standard review	Approved	None posted
Aug 6, 1971	Original applicationNew formulation or manufacturer · Standard review	Approved	None posted

Identifiers

Application: NDA 16983
Drugs@FDA: Overview at FDA
Company: Liebel-Flarsheim Company

Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters